PD-ECGF positivity correlates with better survival, while iNOS has no predictive value for cervical carcinomas treated with radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 1, 2003, Pages 217-221

  Oka, Kuniyuki ^a,c   Suzuki, Yoshiyuki ^b   Iida, Hiroko ^c   Nakano, Takashi ^b  

^a MITO SAISEIKAI GENERAL HOSPITAL   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Cervical squamous cell carcinoma; iNOS; PD ECGF; Prognosis; Radiotherapy

Indexed keywords

CELLS; ENZYMES; PATIENT TREATMENT; TUMORS;

CELL GROWTH;

ONCOLOGY;

NITRIC OXIDE SYNTHASE; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR;

ADULT; AGED; ARTICLE; BIOPSY; CANCER CELL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; UTERINE CERVIX CARCINOMA;

EID: 0042566076     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00436-X     Document Type: Article

References (25)

1. Folkman J., Shing Y. Angiogenesis. J Biol Chem. 267:1992;10931-10934.
2. Furukawa T., Yoshimura A., Sumizawa T., et al. Angiogenic factor. Nature. 356:1992;668.
3. Fox S.B., Moghaddam A., Westwood M., et al. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues An immunohistochemical study . J Pathol. 176:1995;183-190.
4. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide Physiology, pathophysiology and pharmacology . Pharmacol Rev. 43:1991;109-142.
5. Knowles R.G., Moncada S. Nitric oxide synthases in mammals. Biochem J. 298:1994;249-258.
6. Esumi H, Tannenbaum SR. US-Japan Co-operative Cancer Research Program. Seminar of nitric oxide synthase and carcinogenesis. Cancer Res 1994;54:297-301.
7. Annual report on the results of treatment in carcinoma of the uterus, vagina, and ovary. Vol 16. Radiumhemmet, Sweden: FIGO; 1979.
8. Poulsen H.E., Taylor C.W., Sobin L.H. Histological typing of female genital tract tumors. No. 13. 1975;World Health Organization, Geneva.
9. Arai T., Nakano T., Morita S., et al. High-dose-rate remote afterloading intracavitary radiation therapy for cancer of the uterine cervix A 20-year experience . Cancer. 69:1992;175-180.
10. Ueda M., Terai Y., Kumagai K., et al. Correlation between tumor angiogenesis and expression of thymidine phosphorylase and patient outcome in uterine cervical carcinoma. Hum Pathol. 30:1999;1389-1394.
11. Hata K., Takebayashi Y., Iida K., et al. Expression of thymidine phosphorylase in human cervical cancer. Anticancer Res. 19:1999;709-716.
12. Fujimoto J., Sakaguchi H., Hirose R., et al. Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine cervical cancers. Br J Cancer. 79:1999;1249-1254.
13. Haensgen G., Krause U., Becker A., et al. Tumor hypoxia, p53, and prognosis in cervical cancers. Int J Radiat Oncol Biol Phys. 50:2001;865-872.
14. Sawada N., Ishikawa T., Sekiguci F., et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 5:1999;2948-2953.
15. Kodama J., Yoshinouchi M., Seki N., et al. Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in cervical cancer. Int J Oncol. 15:1999;149-154.
16. Tominaga T., Toi M., Ohashi Y., et al. Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients. Clin Breast Cancer. 3:2002;55-64.
17. Fox S.B., Engels K., Comley M., et al. Relationship of elevated tumor thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Ann Oncol. 8:1997;271-275.
18. Yang Q., Barbareschi M., Mori I., et al. Prognostic value of thymidine phosphorylase expression in breast carcinoma. Int J Cancer. 97:2002;512-517.
19. Nakano T., Oka K. Differential values of Ki-67 index and mitotic index of proliferating cell population. Cancer. 72:1993;2401-2408.
20. Oka K., Suzuki Y., Nakano T. High growth fraction at 9 Grays of radiotherapy is associated with a good prognosis for patients with cervical squamous cell carcinoma. Cancer. 89:2000;1526-1531.
21. Kong G., Kim E.K., Kim W.S., et al. Inducible nitric oxide synthase (iNOS) immunoreactivity and its relationship to cell proliferation, apoptosis, angiogenesis, clinicopathologic characteristics, and patient survival in pancreatic cancer. Int J Pancreatol. 29:2001;133-140.
22. Pukkila M.J., Kellokoski J.K., Virtaniemi J.A., et al. Inducible nitric oxide synthase expression in pharyngeal squamous cell carcinoma Relation to p53 expression, clinicopathological data, and survival . Laryngoscope. 112:2002;1084-1088.
23. Aaltomaa S.H., Lipponen P.K., Kosma V.M. Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer. Anticancer Res. 21:2001;3101-3106.
24. Ekmerkcioglu S., Ellerhorst J., Smid C.M., et al. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res. 6:2000;4768-4775.
25. Ropponen K.M., Kellokoski J.K., Lipponen P.K., et al. Expression of inducible nitric oxide synthase in colorectal cancer and its association with prognosis. Scand J Gastroenterol. 35:2000;1204-1211.